Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An Aging Interventions Testing Program: study design and interim report.

Richard A Miller1, David E Harrison, Clinton M Astle

  • 1Department of Pathology and Geriatrics Center, University of Michigan, Ann Arbor VA Medical Center, Ann Arbor, MI 48109-2200, USA. millerr@umich.edu

Aging Cell
|June 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intrinsic capacity and mortality in community-dwelling octogenarians: a network analysis from the ilSIRENTE study.

GeroScience·2026
Same author

The Gut-Muscle Axis in Sarcopenia: Mechanisms, Evidence Gaps and Translational Challenges.

Biomedicines·2026
Same author

Universal transcriptomic hallmarks of mammalian ageing and mortality.

Nature·2026
Same author

Feasibility of home-based, remotely delivered exercise training to improve physical function in older sepsis survivors: a pilot randomized controlled trial.

GeroScience·2026
Same author

Dynamics of genetic and somatic trade-offs in ageing and mortality.

Nature·2026
Same author

Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice.

GeroScience·2026
Same journal

Metabolic Kinases as Regulators of Inter-Organelle Communication in Aging and Age-Related Diseases.

Aging cell·2026
Same journal

A Non-Canonical Role for Hepatocyte MLKL in Promoting Mitochondrial Dysfunction and Senescence in the Aging Liver.

Aging cell·2026
Same journal

EGR1 Mediates Ursodeoxycholic Acid-Promoted Mitophagy to Prevent Postovulatory Aging of Porcine Oocytes.

Aging cell·2026
Same journal

Interplay of the ENS and Microbiota With Murine Gut Epithelium-Derived Organoids in Aging.

Aging cell·2026
Same journal

Age-Associated Senescence of Decidual Macrophages: A Key Mediator of Adverse Pregnancy Outcomes in Advanced Maternal Age.

Aging cell·2026
Same journal

Correction to "Telomerase Knockout in Myeloid Cells Predisposes Mice to Foam Cell Formation, Dyslipidemia, Lung Fibrosis, and Cardiac Dysfunction".

Aging cell·2026
See all related articles

The National Institute on Aging

Area of Science:

  • Gerontology and aging research
  • Drug discovery and development for aging interventions

Background:

  • The National Institute on Aging's Interventions Testing Program (ITP) aims to identify agents that delay aging.
  • Genetically heterogeneous mice are used to model aging processes.
  • Multi-site replication ensures study robustness.

Purpose of the Study:

  • To evaluate the efficacy of four agents (aspirin, nitroflurbiprofen, 4-OH-PBN, and NDGA) in delaying aging rates.
  • To assess the impact of these agents on lifespan and age-dependent physiological changes.

Main Methods:

  • Utilized a standardized four-way cross of genetically heterogeneous mice across three test sites.
  • Administered aspirin, nitroflurbiprofen (NFP), 4-OH-alpha-phenyl-N-tert-butyl nitrone (4-OH-PBN), or nordihydroguiaretic acid (NDGA) to mice.

Related Experiment Videos

  • Conducted interim survival analysis based on median lifespan.

    • Main Results:

    • Nordihydroguiaretic acid (NDGA) significantly improved male mouse survival (P = 0.0004) across multiple sites.
    • No significant lifespan alterations were observed for aspirin, NFP, or 4-OH-PBN.
    • Aspirin showed a non-significant trend towards improved male survival (P = 0.07).

    Conclusions:

    • NDGA demonstrates potential in reducing early mortality in genetically heterogeneous mice.
    • Further research is required to confirm if these agents can extend maximal lifespan.
    • The ITP provides a robust platform for evaluating aging intervention candidates.